Literature DB >> 10807387

Radiation exposure from outpatient radioactive iodine (131I) therapy for thyroid carcinoma.

P W Grigsby1, B A Siegel, S Baker, J O Eichling.   

Abstract

CONTEXT: In May 1997, the US Nuclear Regulatory Commission (NRC) revised its patient release regulations, allowing for outpatient administration of larger activities of sodium iodide 131I than previously permitted.
OBJECTIVE: To measure the radiation exposure to household members from patients receiving outpatient 131I therapy for thyroid carcinoma in accordance with the new regulations.
DESIGN: Consecutive case series from October 1998 to June 1999. SETTING AND PATIENTS: Thirty patients who received outpatient 131I therapy following thyroidectomy for differentiated thyroid carcinoma were enrolled, along with their 65 household members and 17 household pets. MAIN OUTCOME MEASURE: Radiation exposure to household members and 4 rooms in each home, as monitored with dosimeters for 10 days following 131I administration.
RESULTS: The patients received 131I doses ranging from 2.8 to 5.6 GBq (mean, 4.3 GBq). The radiation dose to 65 household members ranged from 0.01 mSv to 1.09 mSv (mean, 0.24 mSv). The dose to 17 household pets ranged from 0.02 mSv to 1.11 mSv (mean, 0.37 mSv). The mean dose to the 4 rooms ranged from 0.17 mSv (kitchen) to 0.58 mSv (bedroom).
CONCLUSION: In our study, 131I doses to household members of patients receiving outpatient 131I therapy were well below the limit (5.0 mSv) mandated by current NRC regulations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10807387     DOI: 10.1001/jama.283.17.2272

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  7 in total

Review 1.  The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy.

Authors:  Scott A Rivkees; Ernest L Mazzaferri; Frederik A Verburg; Christoph Reiners; Markus Luster; Christopher K Breuer; Catherine A Dinauer; Robert Udelsman
Journal:  Endocr Rev       Date:  2011-08-31       Impact factor: 19.871

2.  Selected Radiation Safety Aspects Including Transportation and Lodging After Outpatient 131I Therapy for Differentiated Thyroid Cancer.

Authors:  Cristiane J Gomes-Lima; Di Wu; Pejman H Kharazi; Gauri J Khojekar; Matthew D Ringel; Richard J Vetter; Gary Bloom; Kenneth D Burman; Leonard Wartofsky; Douglas Van Nostrand
Journal:  Thyroid       Date:  2017-12       Impact factor: 6.568

3.  Measurement of the internal dose to families of outpatients treated with 131I for hyperthyroidism.

Authors:  S F Barrington; P Anderson; A G Kettle; R Gadd; W H Thomson; S Batchelor; P J Mountford; L K Harding; M J O'Doherty
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-06       Impact factor: 9.236

4.  Behavior and awareness of thyroid cancer patients in Korea having non-hospitalized low-dose radioiodine treatment with regard to radiation safety.

Authors:  Seog Gyun Kim; Jin Chul Paeng; Jae Seon Eo; Hye Kyung Shim; Keon Wook Kang; June-Key Chung; Myung Chul Lee; Dong Soo Lee
Journal:  Nucl Med Mol Imaging       Date:  2010-11-03

5.  High-Dose Radioiodine Outpatient Treatment: An Initial Experience in Thailand.

Authors:  Danupon Nantajit; Sureerat Saengsuda; Pattama NaNakorn; Yuthana Saengsuda
Journal:  Asia Ocean J Nucl Med Biol       Date:  2015

6.  Higher body weight and distant metastasis are associated with higher radiation exposure to the household environment from patients with thyroid cancer after radioactive iodine therapy.

Authors:  Sheng-Fong Kuo; Tsung-Ying Ho; Miaw-Jene Liou; Kun-Ju Lin; Ru-Chin Cheng; Sheng-Chieh Chan; Bie-Yui Huang; Soh-Ching Ng; Feng-Hsuan Liu; Hung-Yu Chang; Sheng-Hwu Hsieh; Kun-Chun Chiang; Huang-Yang Chen; Ta-You Lo; Chih-Lang Lin; Jen-Der Lin
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

7.  Effective method of measuring the radioactivity of [ 131I]-capsule prior to radioiodine therapy with significant reduction of the radiation exposure to the medical staff.

Authors:  Ulf Lützen; Yi Zhao; Malies Marx; Thea Imme; Isong Assam; Frank-Andre Siebert; Juaraj Culman; Maaz Zuhayra
Journal:  J Appl Clin Med Phys       Date:  2016-07-08       Impact factor: 2.102

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.